The research aims to produce valid information and must use reliable instruments that guarantee accurate and make it quantifiable and possible reproducibility. Allowing the exclusion or at least control prejudice of personal insights and trends that may distort the results.
martes, 2 de noviembre de 2010
Human Immune System Assassin's Tricks Visualized for the First Time
Scientists from the UK and Australia have seen the human immune system's assassin -- a protein called perforin -- in action for the first time. The UK team is based at Birkbeck College where they used powerful electron microscopes to study the mechanism that perforin uses to punch holes in rogue cells.
The research is published on October 31 in Nature.
Professor Helen Saibil, who leads the UK team at Birkbeck College, said: "Perforin is a powerful bullet in the arsenal of our immune system -- without it we could not deal with the thousands of rogue cells that turn up in our bodies through our lives."
"Perforin is our body's weapon of cleansing and death," said project leader Professor James Whisstock from Monash University, Melbourne, Australia.
Perforin works by punching holes in cells that have become cancerous or have been invaded by viruses. The holes let toxic enzymes into the cells, which then destroy them.
If perforin isn't working properly the body can't fight infected cells. And there is evidence from mouse studies that defective perforin leads to an upsurge in malignancy, particularly leukaemia, so says Professor Joe Trapani, head of the Cancer Immunology Program at the Peter MacCallum Cancer Centre in Melbourne, Australia.
The first observations that the human immune system could punch holes in target cells was made by the Nobel Laureate Jules Bordet over 110 years ago, but we have had to wait for the latest advances in structural molecular biology to find out how exactly this happens.
Professor Saibil continued: "From our previous work we already knew that bacterial toxins, such as the one involved in pneumonia, dramatically change shape to punch holes in membranes. We were fascinated by perforin and wanted to know its structure and how that might change in order for it to act as a hole-punching machine."
The structure was revealed by combining information about a single perforin molecule -- visualised using the Australian Synchrotron -- with Professor Saibil's electron microscope images (taken in London) of a ring of perforin molecules clustered together to form a hole in a cell membrane.
Professor Whisstock added: "Now we know how it works, we can start to fine tune it to fight cancer, malaria and diabetes."
Another interesting finding is that the important parts of the perforin molecule are quite similar to those toxins deployed by bacteria such as anthrax, listeria and streptococcus, showing that this method of making holes in cell membranes is quite ancient in evolution. "The molecular structure has survived for close to two billion years, we think," said Professor Trapani.
Perforin is also the culprit when the wrong cells are marked for elimination, either in autoimmune disease conditions, such as early onset diabetes, or in tissue rejection following bone marrow transplantation. So the researchers are now investigating ways to boost perforin for more effective cancer protection and therapy for acute diseases such as cerebral malaria. And with the help of a £600K grant from the Wellcome Trust they are working on potential inhibitors to suppress perforin and counter tissue rejection.
Professor Douglas Kell, BBSRC Chief Executive said: "New technologies in microscopy and synchrotron experiments have opened up tremendous opportunities for molecular biologists. This is a great example where the knowledge we gain about the normal structure and function of a molecule has the potential to underpin important developments in our health and well being."
The lead authors are Ruby Law from Monash University, Natalya Lukoyanova from Birkbeck College, London, and Ilia Voskoboinik from the Peter MacCallum Cancer Centre and the University of Melbourne. The project leaders are: Joe Trapani (Peter Mac), Helen Saibil (Birkbeck) and James Whisstock (Monash). The research was supported by the above institutions, the NHMRC, the ARC, the UK Biotechnology and Biological Sciences Research Council and the Wellcome Trust.
Suscribirse a: Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario